AxoGen
2002
FOUNDED
PUBLIC
STATUS
201-300
EMPLOYEES
AXGN
STOCK SYMBOL
1
INVESTMENTS
$14.31
SHARE PRICE
(As of Friday Closing)
Description
Axogen Inc is a medical technology company. It provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. The firm's product portfolio includes Avance nerve graft, Axoguard nerve connector and nerve protector, Avive soft tissue membrane, Axotouch two-point membrane and Acroval Neurosensory and motor testing system. Its products are available in the United States, Canada, the United Kingdom and other European and International countries. The company generates the majority of its sales in the United States.
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 13631 Progress Boulevard
- Suite 400
- Alachua, FL 32615
- United States
+1 (888) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore AxoGen’s full profile, request a free trial.
AxoGen Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $10.91 - $25.84 | $565M | $15.02 | -$0.69 | 363K | 39.5M |
AxoGen Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 391,053 | 663,792 | 971,926 | 305,076 |
| Revenue | 101,983 | 83,937 | 60,426 | 41,108 |
| EBITDA | (25,002) | (20,338) | (7,415) | (7,713) |
| Net Income | (27,326) | (22,397) | (10,445) | (14,411) |
| Total Assets | 154,192 | 160,173 | 58,875 | 46,360 |
| Total Debt | 3,775 | 63 | 24,545 | 24,312 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AxoGen Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore AxoGen‘s full profile, request access.
Request full access to PitchBookAxoGen Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 0000000 | Private Equity-Backed | Winston-Salem, NC | 00 | 00000 | 000000&0 |
AxoGen Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 30-Sep-2011 | 000000000000000000 | 0000 | Therapeutic Devices | 00000 0000000 |
AxoGen Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000000 | Therapeutic Devices | Texarkana, TX | 0000 |
AxoGen Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore AxoGen‘s full profile, request access.
Request full access to PitchBookAxoGen Executive Team (15)
4 Former Executives
You’re viewing 5 of 15 executives. Get the full list »AxoGen Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Amy Wendell | AxoGen | Board Member | 000 0000 | |
| Gregory Freitag JD | AxoGen | Board Member & General Counsel | 000 0000 | |
| Guido Neels | EW Healthcare Partners | Board Member | 000 0000 | |
| Karen Zaderej | AxoGen | Chief Executive Officer & Chairman | 000 0000 | |
| Mark Gold MD | Self | Board Member | 000 0000 |
5 Former Board Members
You’re viewing 5 of 12 board members. Get the full list »